Factors influencing scar formation following Bacille Calmette-Guérin (BCG) vaccination
Villanueva, Paola (Department of General Medicine, Royal Children's Hospital Melbourne (Austràlia))
Crawford, Nigel W. (Immunisation Service, Royal Children's Hospital Melbourne)
Croda, Mariana Garcia (Universidade Federal do Mato Grosso do Sul (Brasil))
Collopy, Simone (Department of Pediatrics, Universidade Estadual do Rio de Janeiro)
Jardim, Bruno Araújo (Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (Brasil))
de Almeida Pinto Jardim, Tyane (Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (Brasil))
Manning, Laurens (Fiona Stanley Hospital (Austràlia))
Lucas, Michaela (QE2 Medical Centre (Austràlia))
Marshall, Helen (The University of Adelaide and Department of Paediatrics (Austràlia))
Prat i Aymerich, Cristina (Institut Germans Trias i Pujol)
Sawka, Alice (Royal Adelaide Hospital (Austràlia))
Sharma, Ketaki (The Children's Hospital at Westmead (Austràlia))
Troeman, Darren (University Medical Center Utrecht)
Wadia, Ushma (Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute (Austràlia))
Warris, Adilia (Great Ormond Street Hospital, London, UK)
Wood, Nicholas (University of Sydney)
Messina, Nicole L. (Infection and Immunity, Murdoch Children's Research Institute, (Austràlia))
Curtis, Nigel (The Royal Children's Hospital Melbourne)
Pittet, Laure F. (University of Geneva)
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	The prevalence of scar formation following Bacille Calmette-Guérin (BCG) vaccination varies globally. The beneficial off-target effects of BCG are proposed to be stronger amongst children who develop a BCG scar. Within an international randomised trial ('BCG vaccination to reduce the impact of coronavirus disease 2019 (COVID-19) in healthcare workers'; BRACE Trial), this nested prospective cohort study assessed the prevalence of and factors influencing scar formation, as well as participant perception of BCG scarring 12 months following vaccination. Amongst 3071 BCG-recipients, 2341 (76%) developed a BCG scar. Scar prevalence was lowest in Spain and highest in UK. Absence of post-injection wheal (OR 0. 4, 95%CI 0. 2-0. 9), BCG revaccination (OR 1. 7, 95%CI 1. 3-2. 0), female sex (OR 2. 0, 95%CI 1. 7-2. 4), older age (OR 0. 4, 95%CI 0. 4-0. 5) and study country (Brazil OR 1. 6, 95%CI 1. 3-2. 0) influenced BCG scar prevalence. Of the 2341 participants with a BCG scar, 1806 (77%) did not mind having the scar. Participants more likely to not mind were those in Brazil, males and those with a prior BCG vaccination history. The majority (96%) did not regret having the vaccine. Both vaccination-related (amenable to optimisation) and individual-related factors affected BCG scar prevalence 12 months following BCG vaccination of adults, with implications for maximising the effectiveness of BCG vaccination.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	BCG vaccine ; BCG scar ; Vaccination technique ; Vaccine safety
Published in:	Heliyon, Vol. 9 (april 2023) , ISSN 2405-8440

Erratum: 10.1016/j.heliyon.2023.e15821
Article original: https://ddd.uab.cat/record/281658?ln=es
DOI: 10.1016/j.heliyon.2023.e15241
DOI: 10.1016/j.heliyon.2023.e15821
PMID: 37113782
PMID: 37484338

12 p, 2.7 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles